Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 Next >
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers PTGX TAK
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces New Assignments of Directors
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers PFE TAK
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers ACIU TAK
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.